A comparative study of the St. Jude Medical and Björk-Shiley convexo-concave prostheses in isolated valve replacement.
This is a study of 199 consecutive patients who survived isolated mitral or aortic valve replacement with a Björk-Shiley (B-S) or St. Jude Medical (SJM) prostheses. Mean follow-up was 36 months. Preoperative status was similar for both groups (B-S or SMJ). Five year survival rates for mitral valve replacement (MVR) were 91% for B-S and SJM, and for aortic valve replacement (AVR) 96% vs 91% for SJM (p less than 0.06). Linearized incidence of thromboembolism in MVR was 5.62% patient year for BS and 5.23% patient year for SJM (p = NS). Classical risk factors for thromboembolism were evaluated on a univariate analysis: no single risk factor was identified. Only the association of two or more was possibly significant. The presence of inadequate anticoagulation (prothrombin index greater than 50%) was the main risk factor for thromboembolism, as the incidence rate was 19% per patient year when poorly anticoagulated versus 4.6% per patient year incidence in the whole series (p less than 0.01).
Aramendi
J I
JI
Division of Cardiac Surgery, Hospital De Cruces, Cruces-Baracaldo (Vizcaya), Spain.
Castellanos
E
E
Serrano
A
A
Madiedo
J B
JB
Ortiz De Salazar
A
A
Agosti
J
J
D000206:Actuarial Analysis; D000925:Anticoagulants / Q000627:therapeutic use; D001021:Aortic Valve; D006349:Heart Valve Diseases / Q000401:mortality / Q000601:surgery*; D006350:Heart Valve Prosthesis / Q000401:mortality*; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D008943:Mitral Valve; D011183:Postoperative Complications / Q000453:epidemiology*; D011474:Prosthesis Design; D012307:Risk Factors; D013923:Thromboembolism / Q000453:epidemiology*
D000925:Anticoagulants